Rising UTI Burden and Outpatient Care Are Accelerating Global UTI Market Growth at 3.9% CAGR

global Urinary tract infection market was valued at $12.8 billion in 2024 and is projected to reach $19.5 billion by 2035, growing at a CAGR of 3.9% during the forecast period (2025-2035). The global urinary tract infection (UTI) market is expanding steadily due to the rising incidence of UTIs across all age groups, particularly among women, the elderly, and patients with chronic conditions or catheter use. Aging populations and lifestyle-related risk factors are increasing recurrent infection rates, while the shift toward outpatient and ambulatory care is accelerating demand for rapid diagnostics and effective, easy-to-administer treatments.

Browse the full report description of “Urinary Tract Infection Market Size, Share & Trends Analysis by Test Type (Biochemical, Microscopic, and Flow Cytometric), by Indication (Complicated Urinary Tract Infection, Uncomplicated Urinary Tract Infection, and Neurogenic Bladder Infections), and by End User (Hospitals and Clinics, and Home Healthcare) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/urinary-tract-infection-treatment-market

At the same time, growing antimicrobial resistance (AMR) is reshaping therapeutic strategies, driving innovation in novel antibiotics, non-antibiotic therapies, and targeted treatment regimens. Technological advancements in laboratory automation, molecular diagnostics, and point-of-care testing are enabling faster pathogen identification and resistance profiling, supporting timely clinical decision-making and improved patient outcomes.

Key Market Developments Influencing the Global UTI Landscape

• 2024: Increased R&D activity focused on novel oral antibiotics and non-antibiotic therapies designed to combat resistant UTI pathogens.
• 2024-2025: Wider adoption of rapid molecular and automated diagnostic platforms in outpatient clinics and laboratories to enable quicker, more precise treatment decisions.
• 2025: Expansion of antimicrobial stewardship initiatives and guideline-driven care pathways aimed at reducing resistance, treatment failures, and healthcare costs.

Focus on Targeted Therapies, Rapid Diagnostics, and AMR-Aware Treatment Pathways

Industry players are investing in the development of next-generation antimicrobials, combination therapies, and alternative treatment approaches to address AMR concerns. Diagnostic companies are advancing automated and point-of-care testing solutions to support outpatient settings, while healthcare providers are integrating stewardship programs and digital decision-support tools to optimize antibiotic use and reduce recurrence rates.

Market Advances with Innovative Solutions and Strategic Growth

• In 2025, Pfizer Inc. introduced a new broad-spectrum UTI therapeutic, featuring improved efficacy against multidrug-resistant pathogens and a patient-friendly dosing regimen, aimed at enhancing treatment outcomes and reducing recurrence rates globally.
• In 2024, GlaxoSmithKline plc (GSK) completed the acquisition of a biotech firm specializing in urogenital infection diagnostics and therapeutics, strengthening its pipeline with novel targeted agents and rapid diagnostic tools for UTI management.
• In 2025, Johnson & Johnson announced a strategic partnership with a leading global diagnostics company to co-develop advanced point-of-care UTI detection platforms that integrate rapid test results with digital health tracking for better clinical decision-making.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Test Type
• Indication
• End-User

• Competitive Landscape – Abbott Laboratories, Bayer AG, Hoffmann-La Roche Ltd., GlaxoSmithKline(GSK) plc and Pfizer Inc.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Urinary Tract Infection Market Report Segment

By Test Type

• Biochemical Urinary Tract Infection
• Microscopic Urinary Tract Infection
• Flow Cytometric Urinary Tract Infection

By Indication

• Complicated Urinary Tract Infection
• Uncomplicated Urinary Tract Infection
• Neurogenic Bladder Infections

By End-User

• Hospitals and Clinics
• Home Healthcare

Global Urinary Tract Infection Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/urinary-tract-infection-treatment-market